ADHD Medication Side Effects in Children and Adults

ADHD medications produce a recognizable cluster of side effects, with reduced appetite, sleep difficulties, and mood changes topping the list. In a survey of roughly 325 patients, about half reported experiencing at least one side effect from their ADHD medication, though only about a fifth of those effects were rated as very bothersome or worse.¹ That picture, however, shifts considerably depending on the type of medication, the dose, and how long you take it.

The Most Common Side Effects

Stimulant medications, which include methylphenidate-based drugs and amphetamine-based drugs, remain the first-line treatment for ADHD in both children and adults. Their side-effect profile is well documented. A systematic review covering stimulant trials found that the most frequently reported problems were decreased appetite, stomach pain, and elevated heart rate, with the overall consensus being that these effects tend to be manageable and mild.² In real-world patient reports, loss of appetite, trouble sleeping, and mood disturbances were the three most commonly mentioned complaints.³

Non-stimulant medications like atomoxetine tend to produce a somewhat different pattern. A comparative meta-analysis found that while stimulants were more likely to cause appetite loss, insomnia, irritability, and tics, non-stimulants leaned more toward gastrointestinal problems, headaches, and dizziness.⁴ The trade-off between stimulant and non-stimulant side effects is often central to prescribing decisions, especially when a patient has already tried one class and found it intolerable.

Appetite, Weight, and Growth in Children

Appetite suppression is the side effect parents notice first, and understandably it raises concerns about whether a growing child will fall behind in weight and height. The short answer is that stimulants do affect growth, but the impact appears modest and at least partly reversible.

A meta-analysis looking specifically at long-term methylphenidate use found consistent reductions in both height and weight compared to expected growth curves. The impact on weight was most prominent in the first year, while the effect on height showed up within the first two to two-and-a-half years of treatment.⁵ A review in a Canadian family medicine journal noted that the rate of height loss seems relatively small and is likely reversible once treatment stops.⁶

One randomized trial tried structured “weight recovery treatment” strategies in children already showing growth suppression from stimulants. Even with intervention, participants continued to decline in standardized weight and height over the study period, and no strategy produced a reliable rebound in height velocity.⁷ So while stopping medication appears to let kids catch up, managing growth suppression while staying on treatment remains tricky.

For children who start treatment while overweight or obese, the appetite-suppressing effects can actually shift their weight category downward. One study found that about half of children who were overweight and over 40% of those who were obese transitioned to a lower weight category while on stimulant medication.⁸ Whether that shift is a welcome or concerning side effect depends entirely on the individual child’s health picture.

Heart Rate, Blood Pressure, and Short-Term Cardiovascular Effects

Stimulants work partly by increasing the activity of catecholamines like dopamine and norepinephrine, which is why they nudge heart rate and blood pressure upward. A systematic review and meta-analysis covering methylphenidate, amphetamines, and atomoxetine found that all three were associated with a small but statistically significant rise in systolic blood pressure. Amphetamines and atomoxetine also raised diastolic blood pressure and heart rate, while methylphenidate did not have a detectable effect on those two measures.⁹

In a community sample of children, those taking stimulant medication had a heart rate about 12 beats per minute higher and blood pressure about 3 mmHg higher than children without ADHD, after adjusting for age, sex, and body size.¹⁰ These are not dramatic numbers, but they add up to a reason why clinicians typically check blood pressure and pulse at follow-up visits. The pediatric literature has not linked these modest elevations to serious cardiac events in otherwise healthy children.¹¹

Long-Term Cardiovascular Risk in Adults

The short-term blood-pressure picture is reassuring for most people. The longer-term data, however, has gotten more attention recently, and the findings are worth understanding in context.

A large Swedish registry study published in JAMA Psychiatry tracked ADHD medication use over 14 years and found that each additional year of cumulative use was associated with roughly a 4% increase in cardiovascular disease risk. The association was steepest in the first three years of use, with the risk of hypertension climbing substantially at longer durations. After three to five years of cumulative treatment, the odds of developing hypertension were about 70% higher than among people with ADHD who had not used medication.¹²

A separate study in the Journal of the American College of Cardiology looked at adults using at least one defined daily dose per day and found modestly elevated 10-year absolute risks of stroke and heart failure compared to prior users who had stopped. The absolute numbers remained small: roughly a 2% 10-year stroke risk versus about 1.7% in prior users. There was no apparent increase in the risk of acute coronary syndrome.¹³

These are observational studies, and they cannot prove that medication alone caused the elevated risk. People who stay on ADHD medication for many years may differ in various ways from those who stop. Still, the data is consistent enough that adults on long-term treatment should keep up with routine cardiovascular screening and mention their ADHD medication when discussing heart health with a doctor.

Sleep Problems

Insomnia is one of the most complained-about side effects of stimulant medication, but disentangling medication-caused sleep trouble from ADHD-caused sleep trouble is surprisingly difficult. ADHD itself is strongly associated with disrupted sleep, and many people have sleep problems before they ever start medication. A review found that clinical predictors of sleep problems during ADHD treatment include the person’s age, whether they had sleep difficulties before starting medication, and the dose and dosing schedule.¹⁴

In practice, this means that adjusting the timing of a dose, switching from an extended-release to an immediate-release formulation taken earlier in the day, or in some cases switching to a non-stimulant can often address the problem. Some clinicians add a low-dose sleep aid temporarily while the patient adjusts. It is worth tracking sleep patterns before and after starting medication so you and your prescriber have a clear picture of what changed.

Stimulant Rebound

Some people, particularly children, experience a worsening of irritability, hyperactivity, or emotional reactivity as their stimulant wears off each day. This phenomenon is called “rebound.” It can look alarming, especially to parents who see their child become more volatile in the late afternoon or evening than they were before medication altogether.

How common rebound actually is depends on how strictly you define it. One study in hospitalized children observed behavioral deterioration in about 30% of children on at least one stimulant dose, but it was severe enough to warrant stopping treatment in fewer than 10%.¹⁵ A trial of lisdexamfetamine found that only about 3% of children on the medication showed rebound in the afternoon or evening, compared to nearly 10% on placebo, suggesting that some of what looks like rebound may be the natural worsening of ADHD symptoms at the end of the day.¹⁶ The practical fix is usually adjusting the formulation or adding a small short-acting “booster” dose to smooth the transition as the main dose wears off.

Tics and Stimulant Treatment

For years, a popular concern held that stimulant medications could cause or worsen tic disorders. The evidence on this turns out to be more nuanced than the worry suggests.

A meta-analysis of randomized, placebo-controlled trials found that the rate of new or worsened tics in children on stimulants was about 5.7%, which was essentially identical to the 6.5% rate seen in children taking placebo. The risk ratio was 0.99, meaning stimulants did not increase tics at a group level.¹⁷ A critical review reached a similar conclusion: group data show no significant increase, though individual patients may experience a worsening of tics that gets lost in the group averages.¹⁸ If you or your child notice new tics after starting a stimulant, that warrants a conversation with the prescriber, but it does not necessarily mean the medication caused them.

Psychosis Risk With Stimulants

Stimulant-related psychosis is rare but real, and the risk is not evenly distributed across medications. A large cohort study found that episodes of new-onset psychosis occurred at a rate of about 2.4 per 1,000 person-years across both methylphenidate and amphetamine users. Amphetamines were associated with roughly 65% higher odds of a psychotic episode compared to methylphenidate.¹⁹

A recent meta-analysis estimated that among people with ADHD prescribed stimulants, about 2.8% developed psychotic symptoms. The risk was significantly higher with amphetamines than with methylphenidate, and higher stimulant doses were associated with a greater likelihood of psychotic symptoms.²⁰ Adverse-event reporting data similarly found that the adjusted odds of psychotic symptoms were about 60% higher with amphetamines than with methylphenidate, while atomoxetine showed no elevated risk.²¹

This does not mean stimulants are unsafe. For the overwhelming majority of patients, psychosis never occurs. But it is a reason why prescribers should ask about any personal or family history of psychotic illness before starting stimulants, and why new hallucinations, paranoid thinking, or disorganized behavior during treatment should prompt an immediate medication review.

Emotional Blunting and Mood Changes

Beyond diagnosable psychiatric events, many people on stimulants describe subtler emotional changes: feeling flat, less spontaneous, or emotionally dampened. Clinicians sometimes call this “emotional blunting” or “zombie effect.” Research into this phenomenon has been surprisingly scarce. A review found very few studies that systematically examined changes in emotional expression tied to ADHD medication, and no empirical data on how best to manage these responses when they occur.²²

In practice, emotional blunting often correlates with dose. Lowering the dose or switching to a different medication within the same class can help. The challenge is that emotional changes can be hard to distinguish from the natural ebb and flow of mood, making it crucial for patients and caregivers to track how emotional life changes over time on medication.

Atomoxetine and Liver Safety

Atomoxetine, the most established non-stimulant ADHD medication, carries a rare but notable liver safety signal. A comprehensive review found that among roughly 4.3 million patients exposed to atomoxetine over four years, the manufacturer identified three cases where the drug was the probable cause of reversible hepatitis. An additional 133 liver-related events were considered possibly related but had confounding factors. Rare cases of severe liver injury appear in official prescribing labels, including one case that required a liver transplant.²³ Adverse-event database analysis has confirmed that the signal for elevated liver enzymes is strongest with atomoxetine compared to stimulants.²⁴

The absolute risk is tiny, but if you are on atomoxetine and notice dark urine, unexplained nausea, yellowing skin, or upper-right abdominal pain, contact your prescriber promptly.

Substance Abuse and Addiction Concerns

The fear that taking a stimulant for ADHD will lead to substance abuse is one of the most persistent worries among patients and parents. The evidence points in the opposite direction. A large study found that people prescribed ADHD medication had a 31% lower rate of substance abuse compared to those with ADHD who were not medicated, even after controlling for other variables. Longer duration of treatment was associated with an even lower rate.²⁵ Untreated ADHD itself is a well-established risk factor for substance use problems, so medication appears to be protective rather than harmful in this regard.

Drug Holidays

Taking planned breaks from medication, sometimes called “drug holidays,” is a strategy some families and clinicians use to manage side effects. A review spanning four decades of international experience found evidence that longer breaks from medication had a positive effect on child growth, while shorter breaks could reduce insomnia and improve appetite.²⁶ Summer breaks from medication, common in school-age children, are the most familiar version of this approach.

The trade-off is straightforward: time off medication means time with less symptom control. For children whose ADHD primarily affects academic performance, weekend or summer breaks may work well. For adults or children whose symptoms significantly affect relationships, safety, or daily functioning beyond school, breaks may not be practical. There is no universal recommendation, and the decision should be made case by case with a prescriber.

Withdrawal and Discontinuation

Stimulant medications are not generally considered physically addictive at therapeutic doses, and there is no well-established withdrawal syndrome on par with, say, stopping an antidepressant. However, abruptly stopping stimulants is not always seamless. A case report documented an 11-year-old who experienced vomiting, headaches, and light sensitivity after abrupt discontinuation of methylphenidate, and later developed migraines and marked malaise after a dose reduction in lisdexamfetamine.²⁷ Many patients report increased fatigue, low mood, or a return of ADHD symptoms that feels worse than their pre-medication baseline, likely because they have adjusted to functioning with medication support. Tapering rather than abruptly stopping is generally the gentler approach.

ADHD Medication During Pregnancy

Whether to continue ADHD medication during pregnancy is a high-stakes question with genuinely mixed evidence. A systematic review of 12 cohort studies covering over 7.5 million participants found that the majority of studies reported no significant negative effects on maternal or offspring outcomes. One even found that continuing medication reduced the risk of certain negative outcomes, while another suggested stopping might increase the risk of threatened abortion.²⁸

The picture gets more granular with specific drugs. A large study pooling data from the US and Nordic countries found a 28% increased risk of cardiac malformations associated with first-trimester methylphenidate exposure. In absolute terms, that translates to roughly 3 additional infants with congenital heart defects per 1,000 exposed pregnancies. Amphetamines did not show the same signal for cardiac or overall congenital malformations.²⁹ A subsequent meta-analysis, however, found that overall rates of congenital anomalies and miscarriages were not significantly higher among women taking methylphenidate or atomoxetine during pregnancy compared to unexposed women.³⁰

The honest summary is that the evidence is still evolving. The decision to continue, switch, or stop medication during pregnancy involves weighing a possible small increase in risk against the real consequences of untreated ADHD, including accidents, job loss, and impaired self-care. It is a conversation that belongs between the patient, their prescriber, and their obstetrician.

Why Side Effects Vary So Much Between People

One of the more frustrating aspects of ADHD medication is how differently two people can respond to the same drug at the same dose. Genetics play a role, though research here is still early. A study of children on methylphenidate found an association between variations in the CES1 gene and the occurrence of sadness as a side effect.³¹ Another study found that specific variants in norepinephrine-related genes predicted cardiovascular responses to methylphenidate. Children with one genotype showed a heart rate increase of about 12.5% after treatment, while those with a different variant saw only a 2.5% increase.³²

Pharmacogenomic testing, which checks your genetic makeup for clues about how you metabolize specific drugs, is commercially available but not yet standard practice for ADHD prescribing. The science is heading in that direction, but for now, finding the right medication and dose is still largely a process of careful trial and observation. Most prescribers start low, increase gradually, and adjust based on what the patient reports. Keeping a simple log of side effects, including when they occur and how disruptive they are, gives your doctor much better information to work with than a vague “I feel off.”

The Burden of Side Effects on Daily Life

It is easy for clinical discussions about side effects to focus on whether something is “statistically significant” or “clinically concerning” without capturing what it actually feels like to live with these effects every day. A study of 585 adults with ADHD found that over 95% had experienced at least one symptom related to ADHD itself or to treatment side effects in the past month, averaging nearly six symptoms per person. Among those dealing with insomnia or mood instability, roughly half said the impact on their overall well-being was severe. The number of symptoms was also correlated with reduced quality of life, lower likelihood of being employed, and greater impairment at work.

This highlights something that can get lost in the risk-versus-benefit calculus: side effects do not have to be medically dangerous to significantly erode someone’s quality of life. A person who sleeps poorly, feels emotionally flat, and has no appetite is technically experiencing “manageable and mild” adverse effects by clinical standards. But those effects are chipping away at the very things the medication is supposed to help with: functioning, productivity, and well-being. When side effects reach that point, the right move is not to tough it out but to revisit the treatment plan. There are enough medication options, dosing strategies, and adjunct approaches that most people can find a tolerable combination if they and their prescriber are willing to iterate.